Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis: A Suitable Monitoring in Elderly Patients?
Authors:
- Isabelle MahéIMIsabelle Mahé
- Ludovic DrouetLDLudovic Drouet
- Olivier ChassanyOCOlivier Chassany
- Anne-Sophie GrenardAGAnne-Sophie Grenard
- Charles CaulinCCCharles Caulin
- Jean-François BergmannJBJean-François Bergmann
- 1 October 2002
- journal article
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 32 (3) , 134-136
Abstract
Monitoring of anti-Xa activity (aXa) levels is not routinely required in patients receiving enoxaparine at prophylactic dosages, since aXa is supposed to stay below the manufacturer’s recommended range in patients treated for venous thrombosis (0.5–1 IU/ml). In order to aXa in elderly subjects receiving prophylactic enoxaparin, 68 consecutive patients (mean age 82.5 ± 10.7 years) hospitalized in a medical department receiving 4,000 IU enoxaparin daily subcutaneously for the prevention of venous thromboembolic disease were studied. After the first injection of enoxaparin, the aXa of 57.4% patients was superior to 0.5 IU/ml while 69.4% had an aXa higher than 0.5 after 8.4 ± 1.2 days. A negative relationship between aXa and body weight and a trend towards a positive correlation between aXa and age but not with creatinine clearance were noted. Our findings question the opportunity to monitor aXa in elderly patients receiving 4,000 IU enoxaparin as antithrombotic prophylaxis.Keywords
This publication has 3 references indexed in Scilit:
- How and When to Monitor a Patient Treated with Low Molecular Weight HeparinSeminars in Thrombosis and Hemostasis, 2001
- Reliability and Validity of Chest Radiograph Surveillance ProgramsChest, 2001
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999